# Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment

> **NCT01857622** · PHASE3 · COMPLETED · sponsor: **Daiichi Sankyo Co., Ltd.** · enrollment: 93 (actual)

## Conditions studied

- Non-valvular Atrial Fibrillation

## Interventions

- **DRUG:** DU-176b 15mg
- **DRUG:** DU-176b 30mg
- **DRUG:** DU-176b 60mg

## Key facts

- **NCT ID:** NCT01857622
- **Lead sponsor:** Daiichi Sankyo Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2019-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01857622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01857622, "Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01857622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*